These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 30826144)

  • 1. Early warning and response system (EWARS) for dengue outbreaks: Recent advancements towards widespread applications in critical settings.
    Hussain-Alkhateeb L; Kroeger A; Olliaro P; Rocklöv J; Sewe MO; Tejeda G; Benitez D; Gill B; Hakim SL; Gomes Carvalho R; Bowman L; Petzold M
    PLoS One; 2018; 13(5):e0196811. PubMed ID: 29727447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dengue in Malaysia: Factors Associated with Dengue Mortality from a National Registry.
    Liew SM; Khoo EM; Ho BK; Lee YK; Omar M; Ayadurai V; Mohamed Yusoff F; Suli Z; Mudin RN; Goh PP; Chinna K
    PLoS One; 2016; 11(6):e0157631. PubMed ID: 27336440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine.
    Coudeville L; Baurin N; L'Azou M; Guy B
    Vaccine; 2016 Dec; 34(50):6426-6435. PubMed ID: 27601343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study on active and passive epidemiological surveillance for dengue in five countries of Latin America.
    Sarti E; L'Azou M; Mercado M; Kuri P; Siqueira JB; Solis E; Noriega F; Ochiai RL
    Int J Infect Dis; 2016 Mar; 44():44-9. PubMed ID: 26836763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
    Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
    Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
    Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
    Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine.
    Godói IP; Da Silva LVD; Sarker AR; Megiddo I; Morton A; Godman B; Alvarez-Madrazo S; Bennie M; Guerra-Junior AA
    Expert Rev Vaccines; 2018 Dec; 17(12):1123-1133. PubMed ID: 30417706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence rates of neurotropic-like and viscerotropic-like disease in three dengue-endemic countries: Mexico, Brazil, and Malaysia.
    Cohen C; Moreira ED; Nañez H; Nachiappan JP; Arvinder-Singh HS; Huoi C; Nealon J; Sarti E; Puentes-Rosas E; Moureau A; Khromava A;
    Vaccine; 2019 Mar; 37(13):1868-1875. PubMed ID: 30826144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of dengue/dengue hemorrhagic fever in Malaysia--a retrospective epidemiological study 1973-1987. Part I: Dengue hemorrhagic fever (DHF).
    Shekhar KC; Huat OL
    Asia Pac J Public Health; 1992-1993; 6(2):15-25. PubMed ID: 1308765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines and immunization strategies for dengue prevention.
    Liu Y; Liu J; Cheng G
    Emerg Microbes Infect; 2016 Jul; 5(7):e77. PubMed ID: 27436365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.